JPWO2022040447A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022040447A5 JPWO2022040447A5 JP2023512428A JP2023512428A JPWO2022040447A5 JP WO2022040447 A5 JPWO2022040447 A5 JP WO2022040447A5 JP 2023512428 A JP2023512428 A JP 2023512428A JP 2023512428 A JP2023512428 A JP 2023512428A JP WO2022040447 A5 JPWO2022040447 A5 JP WO2022040447A5
- Authority
- JP
- Japan
- Prior art keywords
- gsi
- pharmaceutical product
- semagacestat
- human patient
- mucus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 229940127557 pharmaceutical product Drugs 0.000 claims 16
- 238000000034 method Methods 0.000 claims 15
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 claims 14
- 229950001900 semagacestat Drugs 0.000 claims 14
- 210000003097 mucus Anatomy 0.000 claims 12
- 208000023504 respiratory system disease Diseases 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 6
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 claims 5
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims 5
- OJPLJFIFUQPSJR-INIZCTEOSA-N RO4929097 Chemical compound N1C(=O)[C@@H](NC(=O)C(C)(C(=O)NCC(F)(F)C(F)(F)F)C)C2=CC=CC=C2C2=CC=CC=C21 OJPLJFIFUQPSJR-INIZCTEOSA-N 0.000 claims 5
- 238000009825 accumulation Methods 0.000 claims 5
- 229950009663 crenigacestat Drugs 0.000 claims 5
- 229950001637 nirogacestat Drugs 0.000 claims 5
- XCGJIFAKUZNNOR-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid Chemical compound C1CC(CCC(=O)O)CCC1(S(=O)(=O)C=1C=CC(Cl)=CC=1)C1=CC(F)=CC=C1F XCGJIFAKUZNNOR-UHFFFAOYSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- -1 LY-3056480 Chemical compound 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- NTKBXPWLNROYPE-UHFFFAOYSA-N (2-cyclohexyl-4-methyl-6-oxopyridin-1-yl)oxymethyl dihydrogen phosphate Chemical compound OP(=O)(O)OCON1C(=O)C=C(C)C=C1C1CCCCC1 NTKBXPWLNROYPE-UHFFFAOYSA-N 0.000 claims 2
- AYOUDDAETNMCBW-GSHUGGBRSA-N (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide Chemical compound O=C([C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 AYOUDDAETNMCBW-GSHUGGBRSA-N 0.000 claims 2
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 claims 2
- LIYLTQQDABRNRX-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(C=2C=C(Cl)C(Cl)=CC=2)C(F)=CC=1C1(C(=O)O)CC1 LIYLTQQDABRNRX-UHFFFAOYSA-N 0.000 claims 2
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 2
- 208000025678 Ciliary Motility disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- MURCDOXDAHPNRQ-ZJKZPDEISA-N L-685,458 Chemical compound C([C@@H]([C@H](O)C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-ZJKZPDEISA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229950008567 avagacestat Drugs 0.000 claims 2
- 201000009267 bronchiectasis Diseases 0.000 claims 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 229940070586 fosciclopirox Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 229940069643 itanapraced Drugs 0.000 claims 2
- WDZVWDXOIGQJIO-UHFFFAOYSA-N n-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC1=CC=C(F)C(C2(CCC(CC2)NS(=O)(=O)C(F)(F)F)S(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 WDZVWDXOIGQJIO-UHFFFAOYSA-N 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068235P | 2020-08-20 | 2020-08-20 | |
| US63/068,235 | 2020-08-20 | ||
| PCT/US2021/046742 WO2022040447A2 (en) | 2020-08-20 | 2021-08-19 | Methods for treating respiratory diseases characterized by mucus hypersecretion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538125A JP2023538125A (ja) | 2023-09-06 |
| JPWO2022040447A5 true JPWO2022040447A5 (https=) | 2024-08-20 |
| JP2023538125A5 JP2023538125A5 (https=) | 2024-08-20 |
Family
ID=80323184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512428A Pending JP2023538125A (ja) | 2020-08-20 | 2021-08-19 | 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277550A1 (https=) |
| EP (1) | EP4199914A4 (https=) |
| JP (1) | JP2023538125A (https=) |
| KR (1) | KR20230052954A (https=) |
| CN (1) | CN116033895A (https=) |
| AU (1) | AU2021329507A1 (https=) |
| BR (1) | BR112023002651A2 (https=) |
| CA (1) | CA3188234A1 (https=) |
| IL (1) | IL300405A (https=) |
| MX (1) | MX2023001993A (https=) |
| WO (1) | WO2022040447A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4268824A1 (en) * | 2022-04-26 | 2023-11-01 | Manros Therapeutics | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament |
| WO2024112356A1 (en) * | 2022-11-23 | 2024-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| SE0101004D0 (sv) | 2001-03-21 | 2001-03-21 | Astrazeneca Ab | New measuring technique |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CA2644136A1 (en) * | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| EP2674428B1 (en) | 2006-04-07 | 2016-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| US8299059B2 (en) | 2009-10-30 | 2012-10-30 | Eli Lilly And Company | Crystalline compound and a process for its preparation |
| PT3030568T (pt) | 2013-08-08 | 2018-12-24 | Galapagos Nv | Tieno[2,3-c]piranos como moduladores de cftr |
| EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| BR112018007021B1 (pt) | 2015-10-06 | 2024-01-09 | Proteostasis Therapeutics, Inc | Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística |
| US9890149B2 (en) | 2015-10-07 | 2018-02-13 | NuBridge BioSciences | Isothiazole derivatives as CFTR modulators |
| BR112018007161B1 (pt) | 2015-10-09 | 2024-01-16 | Galapagos Nv | COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA |
| AU2017256172A1 (en) | 2016-04-26 | 2018-09-06 | AbbVie S.à.r.l. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| MX387203B (es) | 2016-11-18 | 2025-03-18 | Cystic Fibrosis Found | Pirrolopirimidinas como potenciadores de cftr. |
| SG10201911076QA (en) | 2016-12-16 | 2020-01-30 | Cystic Fibrosis Found | Bycyclic heteroaryl derivatives as cftr potentiators |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| KR20250030524A (ko) | 2019-08-09 | 2025-03-05 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도 |
-
2021
- 2021-08-19 WO PCT/US2021/046742 patent/WO2022040447A2/en not_active Ceased
- 2021-08-19 EP EP21859146.9A patent/EP4199914A4/en active Pending
- 2021-08-19 BR BR112023002651A patent/BR112023002651A2/pt unknown
- 2021-08-19 AU AU2021329507A patent/AU2021329507A1/en active Pending
- 2021-08-19 IL IL300405A patent/IL300405A/en unknown
- 2021-08-19 CA CA3188234A patent/CA3188234A1/en active Pending
- 2021-08-19 US US18/018,999 patent/US20230277550A1/en active Pending
- 2021-08-19 JP JP2023512428A patent/JP2023538125A/ja active Pending
- 2021-08-19 KR KR1020237009414A patent/KR20230052954A/ko active Pending
- 2021-08-19 MX MX2023001993A patent/MX2023001993A/es unknown
- 2021-08-19 CN CN202180051358.5A patent/CN116033895A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barach et al. | Inhalation of penicillin aerosol in patients with bronchial asthma, chronic bronchitis, bronchiectasis and lung abscess: preliminary report | |
| JP2023041862A5 (https=) | ||
| RU2007130700A (ru) | Комбинация соединений метилксантина и стероидов для лечения хронических распираторных заболеваний | |
| JP2024071397A5 (https=) | ||
| ZA200303845B (en) | Inhalation of nitric oxide. | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| IL292612A (en) | Treatment methods using mtorc1 modulator | |
| Ferguson | Update on pharmacologic therapy for chronic obstructive pulmonary disease | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JPWO2022040447A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| ES2248131T3 (es) | Combinacion de loteprednol y agonistas de adrenoceptor beta2 y su utilizacion por inhalacion para el tratamiento del asma bronquial. | |
| WO2022040447A3 (en) | Methods for treating respiratory diseases characterized by mucus hypersecretion | |
| JP2021530568A5 (https=) | ||
| US20120101076A1 (en) | Carbonate derivatives for the treatment of cough | |
| US20020198228A1 (en) | Composition and method for the treatment of respiratory desease | |
| JP2021176903A (ja) | イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの応用 | |
| CN104427982B (zh) | 治疗炎性和免疫障碍的组合物 | |
| JPWO2023043999A5 (https=) | ||
| JP2016504358A (ja) | オキシブチニンを投与するための方法および組成物 | |
| Lozewicz | Bladder outflow obstruction induced by ipratropium bromide | |
| RU2190422C1 (ru) | Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием | |
| RU2231370C2 (ru) | Способ лечения больных с заболеваниями, сопровождающимися явлениями бронхообструкции | |
| JPWO2022258972A5 (https=) |